Jacob A. Torres, Nickolas Holznecht, David A. Asplund, Bradley C. Kroes, Tselmeg Amarlkhagva, Matthias M. Haeffner, Elizabeth H. Sharpe, Stella Koestner, Sebastian Strubl, Margaret F. Schimmel, Samantha Kruger, Shagun Agrawal, Brina A. Aceves, Muthusamy Thangaraju, Thomas Weimbs

A new study has highlighted a groundbreaking approach to managing Autosomal Dominant Polycystic Kidney Disease (ADPKD), a life-threatening genetic condition affecting millions worldwide. Researchers from the Weimbs lab show that the natural compound beta-hydroxybutyrate (BHB), which the body produces during fasting or following a ketogenic diet, can significantly slow or even reverse the progression of the disease in animal models.The study explored how fasting, time-restricted feeding, and BHB supplementation influence ADPKD. Remarkably, simply supplementing with BHB mimicked the beneficial effects of fasting, improving kidney function and reducing disease markers without requiring strict dietary changes. This effect is believed to stem from BHB’s ability to enhance cellular energy production and reduce harmful inflammation in the kidneys.These findings point to a potentially safe, cost-effective, and accessible therapy for managing ADPKD, offering hope to those for whom current treatments are either ineffective or inaccessible. Further clinical trials are needed, but the results so far are promising, paving the way for new, non-invasive treatment strategies for kidney diseases.